Detailed Review of Forecasted Birch Allergy Market is included in the report, covering drug outreach in the 7MM

The Birch Allergy market is expected to witness a significant positive shift owing to the positive outcomes of the several products during the developmental stage by key players such Regeneron Pharmaceuticals, ALK-Abello, and others.

The Birch Allergy market report provides current treatment practices, Birch Allergy emerging drugs, Birch Allergy market share of the individual therapies, current and forecasted Birch Allergy market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Birch Allergy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Key takeaways from the Birch Allergy Market Research Report

• According to the French company, DJO Global, the pooled prevalence estimates indicate that Birch Allergy affects 23% of adults aged 18-65 and 35% of people aged over 65 in France.

• According to the Biedermann wt al., 2019, the prevalence of Rosaceae IgE sensitization in birch pollen-allergic patients is much higher than that of the general European population, in whom IgE sensitization to hazelnut and apple is 9.3% and 6.5%, respectively.

• The leading Birch Allergy Market Companies includes Regeneron Pharmaceuticals, ALK-Abello, and others.

• Promising Birch Allergy Pipeline Therapies includes REGN5713, DM-101, Recombinant birch pollen, ALK tree AIT 0.5 DU, Birch pollen allergoid, and others.

• According to DelveInsight, Birch Allergy market in 7MM is expected to change in the study period 2019-2032.

Discover which therapies are expected to grab the major Birch Allergy market share, click here for Birch Allergy Market Research Report @ https://www.delveinsight.com/sample-request/birch-allergy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recent Developmental Activities in the Birch Allergy Treatment Landscape

• REGN5713-5714-5715 is an investigational combination of three fully human monoclonal antibodies designed to treat allergic inflammatory conditions caused by the allergen Betv1, which is the main allergen responsible for birch pollen allergies. Birch allergy can trigger reactions such as allergic rhinitis and asthma. The Bet v1-specific mAbs (REGN5713, REGN5714, and REGN5715) were generated using Regeneron's VelocImmune platform. Preclinical studies demonstrated that the three mAbs bind independently and non-competitively to Bet v 1 and that all three together provided maximal inhibition of Bet v 1 binding to human polyclonal IgE and potently blocked basophil activation ex vivo and mast cell degranulation in vivo. Recently, its Phase III (NCT04709575) trial to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season has been completed.

• ILT-101 is developing by ILTOO Pharma, low-dose IL-2 (ld-IL2) specifically targets and activates regulatory T cells (Tregs), which are cells that regulate immune responses. Thus by stimulating Tregs, ld-IL2 would control allergic responses. ILTOO pharma in collaboration with Assistance Publique Hopitaux de Paris has completed a Phase II Rhinil-2 (NCT03776643) trial in allergic Rhinoconjunctivitis and Hypersensitivity in France.

Birch Allergy Overview
Allergy is a condition that occurs when the body (the immune system) overreacts to something in the environment (triggers). It is caused by allergens, which are usually harmless substances but trigger an allergic reaction in some people. When the symptoms occur in late summer or early fall, some people call it hay fever.

Birch Allergy Epidemiology Segmentation in the 7MM
• Total Prevalent Cases
• Total Diagnosed Cases
• Total Treated Cases

Download the report to understand which factors are driving Birch Allergy Market Trends, click here for Birch Allergy Market Forecast @ https://www.delveinsight.com/sample-request/birch-allergy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Birch Allergy Treatment Market
The first-line treatment of allergy involves the avoidance of relevant allergens (e.g., house dust mites, molds, pets, pollens) and irritants (e.g., tobacco smoke). Patients allergic to house dust mites should be instructed to use allergen-impermeable covers for bedding and to keep the relative humidity in the home below 50% (to inhibit mite growth). The treatment goal for Birch Allergy is relief of symptoms. Therapeutic options available to achieve this goal include avoidance measures, nasal saline irrigation, oral antihistamines, intranasal corticosteroids, combination intranasal corticosteroid/antihistamine sprays; leukotriene receptor antagonists (LTRAs), and allergen immunotherapy. Other therapies that may be useful in select patients include decongestants and oral corticosteroids. If the patient's symptoms persist despite appropriate treatment, referral to an allergist should be considered.

Birch Allergy Emerging Therapy Assessment
Birch allergy is a very common disease and comprehensively studied, therefore, the emerging landscape of this condition is not very robust. As per the secondary domain searches and exploring clinical trials sites, it has been observed that number of clinical trials had been registered for this indication. Key players, such as, Regeneron Pharmaceuticals, ALK-Abelló A/S and ILTOO Pharma etc.

Learn more about the Birch Allergy FDA-approved drugs, click here for Birch Allergy Treatment Market @ https://www.delveinsight.com/sample-request/birch-allergy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Birch Allergy Market Research Report

• Coverage- 7MM

• Birch Allergy Market Companies- Regeneron Pharmaceuticals, ALK-Abello, and others.

• Birch Allergy Pipeline Therapies- REGN5713, DM-101, Recombinant birch pollen, ALK tree AIT 0.5 DU, Birch pollen allergoid, and others.

• Birch Allergy Market Dynamics: Birch Allergy Market Drivers and Barriers

• Birch Allergy Market Access Reimbursement, Unmet Needs, Analyst Views

Discover more about Birch Allergy Drugs in development, click here for Birch Allergy Market Drugs @ https://www.delveinsight.com/sample-request/birch-allergy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Birch Allergy
3. Competitive Intelligence Analysis for Birch Allergy
4. Birch Allergy: Market Overview at a Glance
5. Birch Allergy: Disease Background and Overview
6. Patient Journey
7. Birch Allergy Epidemiology and Patient Population
8. Birch Allergy Treatment Algorithm, Current Treatment, and Medical Practices
9. Birch Allergy Unmet Needs
10. Key Endpoints of Birch Allergy Treatment
11. Birch Allergy Marketed Products
12. Birch Allergy Emerging Therapies
13. Birch Allergy: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Birch Allergy
17. KOL Views
18. Birch Allergy Market Drivers
19. Birch Allergy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Read more about the Birch Allergy Market Dynamics of the report, click here for Birch Allergy Market Barriers and Drivers @ https://www.delveinsight.com/sample-request/birch-allergy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.